Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ --

  • Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60
  • Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP EPS Guidance of $2.54-$2.56
  • Delivers Revenue of $4.658 Billion, an Increase of 3.3 Percent (Up 3.6 Percent Excluding Foreign Exchange); Revenue Up 10.9 Percent Excluding Exchange and TriCor/Trilipix Due to Loss of Exclusivity
  • Revenue Growth Reflects 19.1 Percent Global Sales Growth from HUMIRA and Strong Growth from Other Products Including Synthroid, Creon, Zemplar and Duodopa
  • Strong R&D Investment Supports Pipeline Advancements Including the Initiation of a Large Single-Agent Study of ABT-199 in CLL, Start of a Second Phase 3 Study of Elagolix in Endometriosis, and Significant Progress Toward the Completion of our Comprehensive Global Phase 3 HCV Program
  • Continues to Enhance Early-Stage Pipeline with Two New Collaborations in Inflammatory Diseases and Cystic Fibrosis
  • AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2013.

    "Our third-quarter performance demonstrates the strength and durability of our product portfolio and the continued execution of our key strategic priorities as an independent biopharmaceutical company," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.  "Our mid- to late-stage pipeline contains a number of potentially significant opportunities, and we look forward to a series of milestones across our pipeline in the coming months."

    Third-Quarter Results

  • Worldwide sales were $4.658 billion in the third quarter, up 3.3 percent.  On an operational basis, sales increased 3.6 percent, excluding a 0.3 percent unfavorable impact from foreign exchange rate fluctuatio
    '/>"/>

  • SOURCE AbbVie
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. AbbVie Named a Science Top Employer
    2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
    6. AbbVie Declares Quarterly Dividend
    7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
    9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
    10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
    11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
    (Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
    (Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
    Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
    ... Cetero Research , the leading early-stage contract ... "Jay" Dixon to Senior Vice President, Quality and Compliance. ... pharmaceutical, biotechnology and CRO industries, and will bring his ... market leadership position. (Photo:   http://photos.prnewswire.com/prnh/20110426/PH89541 ...
    ... Protect Pharmaceutical Corporation (OTCBB: PRTT) today announced its Board ... Sesha as its Chief Executive Officer and Chairman of ... the Chief Operating Officer and Board Member in March ... where he was the Founder and CEO. ...
    Cached Medicine Technology:Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance 2Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer 2
    (Date:1/22/2015)... with its top dressmaking technologies, has been a leading dress ... its latest designs of wedding dresses and launching a site-wide ... all the fresh new products are designed for 2015, and ... off. All the clothes from LunaDress follow up with the ...
    (Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
    (Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
    (Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
    (Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
    Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
    ... to revolutionize senior home care industry!PALO ALTO, Calif., ... Alto, California released its new caregiver training program ... exclusive to Home Care Assistance 1-866-4-LiveIn(TM), promotes longevity ... an emphasis on lifestyle, healthy diet, physical activity, ...
    ... Kidz-Med ThermofocusWESTON, Fla., May 22 Kidz-Med, Inc., a ... is excited to see that awareness for a new ... taking a child,s temperature with the Kidz-Med Thermofocus 5-in-1 ... The Doctors , renowned pediatrician Dr. Jim Sears, ...
    ... 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; ... today provided an update on its Phase III ... bladder cancer. On March 31st, the Company announced ... Phase III registration trial evaluating Urocidin in the ...
    ... protein linked to tumor growth for clues to better treatments ... have found that levels of the protein caveolin-1 found in ... predict a patient,s prognosis and may provide a pathway to ... a role in how cells absorb things, in the stromal ...
    ... is what leads to well-being , , FRIDAY, May 22 (HealthDay ... may sound like a sure ticket to happiness, but a ... Rochester in New York tracked 147 college graduates, evaluating their ... one year after graduation, and then 12 months later. , ...
    ... to manufacturers by month,s end , , FRIDAY, May 22 (HealthDay ... a bit nearer Friday, with government health officials saying they ... shot. , "Today CDC received, from one institution, a candidate ... Science and Public Health Program said during a Friday news ...
    Cached Medicine News:Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 2Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 3Health News:Awareness Increases on New Health and Safety Technology for Kids 2Health News:Awareness Increases on New Health and Safety Technology for Kids 3Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 2Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 3Health News:Looks, Money, Fame Don't Bring Happiness 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 3Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 4Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 5Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 6Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 7Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 8Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 9Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 10Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 11Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 12Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 13
    ... motor was specifically developed for use in hand ... orientation is reflected in the design of the ... K-wire chuck and saw attachment, which all allow ... thanks to the systems high torque, it is ...
    ... Stenoscop Plus is a truly flexible system ... wide range of applications, inlcuding orthopedics, abdominal ... placement, and more. , ,By ... intensifier sizes, evolutive memory capacities and a ...
    The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes...
    ... Medennium is an innovative device used ... duct, and conserve the eye's natural ... a range of punctum sizes. Made ... SmartPLUG adjusts to the exact shape ...
    Medicine Products: